Heart failure (HF) has become a significant public health problem as a major cause of death among the elderly population in many countries. However, osteoporosis is a multifactorial skeletal disease, which is characterized by low bone mass and microarchitectural deterioration of bone tissue determined according to bone mineral density (BMD). Approximately 21% of women and 6% of men aged 50 years or older have osteoporosis, which is a major public health concern.

Tartrate-resistant acid phosphate (TRACP) is known as type-5 acid phosphatase and purple acid phosphatase. TRACP is an iron-containing glycoprotein expressed in high amounts on bone-resorbing osteoclasts, inflammatory macrophages, and dendritic cells. There are 2 forms of TRACP in the circulating human blood. TRACP type 5a is known as a biomarker of the systemic inflammatory burden in patients with chronic inflammatory diseases such as sarcoidosis and rheumatoid arthritis. TRACP type 5b (TRACP5b), secreted by osteoclasts, is elevated in patients with osteoporosis, and is used as a specific and sensitive marker of bone resorption and bone remodelling.

Osteoporosis is prevalent in patients with HF and might associate with the pathogenesis of HF. The prevalence of HF and osteoporosis increases with aging, and osteoporosis increases cardiovascular risks. Low BMD, namely, osteoporosis, increases the risk of development of cardiovascular diseases, and is a novel biomarker that indicates increased HF risk, independent of established risk factors. HF and osteoporosis share common pathophysiology, including increased parathyroid hormone levels, activation of the renin-angiotensin-aldosterone system, and oxidative stress. In addition, loop diuretic use is associated with increased loss in BMD in men, and with fractures in postmenopausal women. Osteoporosis might be of substantial significance in patients with HF. It has been reported that lower BMD is associated with increased mortality, need for implantation of a left ventricular assist
device, and inotrope dependency in patients with HF. However, the association between serum TRACP5b levels and the prognosis in HF patients remains unclear.

In the present study, we aimed to investigate the effect of serum levels of TRACP5b on HF prognosis, underlying clinical background, cardiac function, and exercise capacity.

Methods
This was a prospective observational study of 688 consecutive decompensated HF patients who were discharged alive from Fukushima Medical University Hospital between 2016 and 2019. The diagnosis of decompensated HF was made by each patient’s attending cardiologist and finally confirmed by the chief physician group on the basis of the HF guidelines. Namely, HF was characterized by typical symptoms (eg, breathlessness, ankle swelling, and fatigue) that might be accompanied by signs (eg, elevated jugular venous pressure, pulmonary crackles, and peripheral edema) caused by a structural and/or functional cardiac abnormality. Blood samples were obtained when the patients were at stable condition before hospital discharge each morning. Patients with acute coronary syndrome and dialysis were excluded. Patients were divided into tertiles on the basis of serum TRACP5b levels: first (TRACP5b < 316 mU/dL, n = 229), second (TRACP5b 316-489 mU/dL, n = 229), and third (TRACP5b ≥ 490 mU/dL, n = 230).

We compared the patient baseline characteristics (eg, blood pressure, heart rate, New York Heart Association [NYHA] classification, comorbidity, laboratory data, echocardiography) at stable condition before hospital discharge and their postdischarge prognosis. The patients were followed-up until January 2020 for cardiac death, and cardiac events defined as composites of cardiac death or unplanned rehospitalization for HF treatment. For patients who experienced 2 or more events, only the first event was included in the analysis. Cardiac death was classified by experienced cardiologists as death caused by worsened HF in accordance with the Framingham criteria, ventricular tachyarrhythmia documented using electrocardiogram or implantable devices, acute coronary syndrome, or sudden cardiac death. Worsening HF was defined as unplanned hospitalization because of worsening HF. The status and/or dates of death of all patients were obtained from the patient medical records or the attending physicians at the patient’s referring hospital. Because these patients visited their referring hospital monthly or bimonthly, we were able to follow-up on all patients. Survival time was calculated from the date of hospitalization until the date of death or last follow-up. Written informed consent was obtained from all study subjects at discharge. This study complied with the Declaration of Helsinki and the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement.

We evaluated several comorbidities (ie, hypertension, diabetes mellitus, dyslipidemia, chronic kidney disease [CKD], anemia), with patients in a stable condition before hospital discharge, which often coexist and are associated with prognosis in HF patients. Comorbidities were defined in accordance with our previous studies. Hypertension was defined as the previous use of antihypertensive drugs for treatment of hypertension, and/or a systolic blood pressure of ≥ 140 mm Hg, and/or a diastolic blood pressure of ≥ 90 mm Hg. The diagnosis of decompensated HF was made by each patient’s attending cardiologist and finally confirmed by the chief physician group on the basis of the HF guidelines.
mm Hg. Diabetes mellitus was defined as the previous use of antidiabetic drugs, a fasting glucose value of ≥ 126 mg/dL, a casual glucose value of ≥ 200 mg/dL, and/or a hemoglobin A1c percentage of ≥ 6.5% (National Glycohemoglobin Standardization Program). Dyslipidemia was defined as the previous use of cholesterol-lowering drugs, a triglyceride value of ≥ 150 mg/dL, a low-density lipoprotein cholesterol value of ≥ 140 mg/dL, and/or a high-density lipoprotein cholesterol value of < 40 mg/dL. CKD was defined as estimated glomerular filtration rate of < 60 mL/min/1.73 m² using a 3-variable Japanese equation. Anemia was defined as hemoglobin levels of < 12.0 g/dL in women and < 13.0 g/dL in men. Atrial fibrillation was identified using an electrocardiogram performed during hospitalization and/or from medical records.

**Measurement of blood samples**

Blood samples were obtained with the patient in stable condition before hospital discharge in morning. Serum TRACP5b was measured using fragment-absorbed immunocapture enzymatic assay using an Osteolinks TRACP5b kit (Nittobo Medical, Tokyo, Japan). Sensitivity of this assay is 19.2 mU/dL, the interassay coefficient of variation (CV), intraassay CV, and overall CV of this measurement are 7.3%, 4.9% and 8.8%, respectively. Anemia was defined as the previous use of antidiabetic drugs, a fasting glucose value of ≥ 126 mg/dL, and/or a hemoglobin A1c percentage of ≥ 6.5% (National Glycohemoglobin Standardization Program). Dyslipidemia was defined as the previous use of cholesterol-lowering drugs, a triglyceride value of ≥ 150 mg/dL, a low-density lipoprotein cholesterol value of ≥ 140 mg/dL, and/or a high-density lipoprotein cholesterol value of < 40 mg/dL. CKD was defined as estimated glomerular filtration rate of < 60 mL/min/1.73 m² using a 3-variable Japanese equation. Anemia was defined as hemoglobin levels of < 12.0 g/dL in women and < 13.0 g/dL in men. Atrial fibrillation was identified using an electrocardiogram performed during hospitalization and/or from medical records.

**Echocardiography**

Echocardiography was performed blindly by experienced echocardiographers using standard techniques with the patient in stable condition before hospital discharge. The echocardiographic parameters investigated included left ventricular end-diastolic volume, left ventricular end-systolic volume, left ventricular ejection fraction (LVEF), interventricular septum, posterior wall, left ventricular mass index (LVMi), left atrial volume, tricuspid valve regurgitation pressure gradient, inferior vena cava, right ventricular diastolic area, right ventricular systolic area, and right ventricular fractional area change. The LVEF was calculated using Simpson’s method in 4-chamber view. LVEF < 40% was considered reduced LVEF, 40%-49% LVEF was considered midrange LVEF, and LVEF ≥ 50% was considered preserved LVEF. The right ventricular fractional area change, defined as (end diastolic area – end systolic area)/end diastolic area × 100, was used as a measure of right ventricular systolic function. All measurements were performed using ultrasound systems (Acuson Sequoia; Siemens Medical Solutions USA, Inc, Mountain View, CA).

**Cardiopulmonary exercise testing**

The patients underwent incremental symptom-limited exercise testing while in a stable condition before hospital discharge, using an upright cycle ergometer with a ramp protocol (Strength Ergo 8; Fukuda Densi Co Ltd, Tokyo, Japan). Breath-by-breath oxygen consumption (VO2), carbon dioxide production (VCO2), and minute ventilation (VE) were measured during exercise using an AE-300S respiratory monitor (Minato Medical Science, Osaka, Japan). Peak VO2 was measured as an average of the last 30 seconds of exercise. Ventilatory response to exercise (slope of the relationship between ventilation and VCO2 [VE/VCO2 slope]) was calculated as the regression slope relating VE to CO2 from the start of exercise until the respiratory compensation point (the time at which ventilation is stimulated by CO2 output and end-tidal CO2 tension begins to decrease). The ventilatory anaerobic threshold was calculated with the V-slope method.

**Statistical analysis**

Parametric variables are presented as mean ± SD, nonparametric variables (eg, C-reactive protein and BNP) are presented as median and interquartile range, and categorical variables are expressed as numbers and percentages. The χ² test was used for comparisons of categorical variables. We used the analysis of variance for continuous variables, followed by Bonferroni post hoc test. We performed multiple regression analysis, allowing for interaction between serum TRACP5b level and clinical confounding factors: age, sex, NYHA functional class, presence of ischemic etiology, hypertension, diabetes, dyslipidemia, CKD, anemia, and atrial fibrillation. Correlations between serum TRACP5b levels and other parameters (eg, laboratory data, echocardiography, and cardiopulmonary exercise test) were assessed using Spearman correlation analysis. Kaplan-Meier analysis was used for presenting the cardiac death and cardiac events, and the log rank test was used for initial comparisons. The prognostic value was tested using univariable and multivariable Cox proportional hazard analyses. In the multivariable Cox proportional hazard analysis, to prepare for potential confounding, because of small event and sample size and presence of multicollinearity between TRACP5b and other variables (eg, BNP), we considered the following clinical factors: age, sex, NYHA class, blood pressure, ischemic etiology, reduced LVEF, hypertension, diabetes, CKD, anemia, atrial fibrillation, and TRACP5b. Univariable parameters with P values of < 0.10 were included in the multivariable analysis. A P value of < 0.05 was considered statistically significant for all comparisons. All analyses were performed using a statistical software package (SPSS version 24.0; IBM Corp, Armonk, NY).
Table 1. Comparisons of clinical characteristics of patients (N = 688)

| Characteristic          | TRACP5b < 316 (n = 229) | TRACP5b 316-489 (n = 229) | TRACP5b ≥ 490 (n = 230) | P    |
|-------------------------|--------------------------|---------------------------|-------------------------|------|
| TRACP5b, mU/dL          | 229.1 ± 54.6             | 393.9 ± 49.6*             | 707.5 ± 204.9*          | < 0.001 |
| Age, years              | 64.2 ± 15.1              | 67.3 ± 15.2               | 71.9 ± 12.8*            | < 0.001 |
| Female sex              | 81 (35.4)                | 99 (43.2)                 | 116 (50.4)              | 0.005 |
| Systolic blood pressure, mm Hg | 126.7 ± 27.2           | 126.3 ± 24.9              | 122.1 ± 25.8            | 0.110 |
| Heart rate, bpm         | 78.6 ± 23.8              | 77.9 ± 25.5               | 75.9 ± 21.2             | 0.454 |
| NYHA class III/IV       | 16 (7.0)                 | 12 (5.2)                  | 19 (8.3)                | 0.436 |
| Ischemic etiology       | 52 (22.7)                | 56 (24.5)                 | 40 (17.4)               | 0.159 |
| LVEF reduced/midrange/preserved | 78 (34.1)/21 (9.2)/130 (56.8) | 84 (36.7)/23 (10.0)/122 (53.3) | 97 (42.2)/18 (7.8)/115 (50.0) | 0.446 |

Comorbidities

- Hypertension: 141 (61.6) vs 138 (60.3) vs 142 (61.7), P = 0.939
- Diabetes: 84 (36.7) vs 83 (36.2) vs 90 (39.1), P = 0.789
- Dyslipidemia: 154 (67.2) vs 161 (70.3) vs 138 (60.0), P = 0.057
- CKD: 117 (51.1) vs 122 (53.3) vs 141 (61.3), P = 0.068
- Anemia: 96 (41.9) vs 107 (46.7) vs 126 (54.8), P = 0.021
- AF: 74 (32.3) vs 76 (33.2) vs 94 (40.9), P = 0.108

Treatment

- RAS inhibitors: 155 (67.7) vs 160 (69.9) vs 146 (63.5), P = 0.334
- ß-Blockers: 145 (63.3) vs 162 (70.7) vs 152 (66.1), P = 0.234
- Diuretics: 150 (65.5) vs 164 (71.6) vs 177 (77.0), P = 0.025
- Inotropic: 34 (14.8) vs 27 (11.8) vs 26 (11.3), P = 0.465
- CCBs: 78 (34.1) vs 82 (35.8) vs 76 (33.0), P = 0.820
- Statins: 92 (40.2) vs 98 (42.8) vs 99 (43.0), P = 0.788
- Implantable devices: 52 (22.7) vs 55 (24.0) vs 71 (30.9), P = 0.100

Data are presented as n (%) or mean (SD), except where otherwise noted.

AF, atrial fibrillation; CCB, calcium channel blocker; CKD, chronic kidney disease; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; TRACP5b, tartrate-resistant acid phosphatase type 5b; RAS, renin-angiotensin-aldosterone system.

* P < 0.01 vs first tertile.
1 P < 0.01 vs second tertile.

Results

The average TRACP5b level of the present study’s population was 443.9 ± 235.1 mU/dL (range, 68-1500). The comparisons of the clinical features among tertiles are shown in Table 1. Although age was significantly higher, the prevalence of female sex and anemia, and the use of diuretics were significantly higher in the third tertile; no significant differences in blood pressure, heart rate, NYHA class III or IV, ischemic etiology, other comorbidities, or medications were observed among the tertiles. In the laboratory data (Table 2), white blood cell count, hemoglobin, estimated glomerular filtration rate (eGFR), and chloride were lowest, and blood urea nitrogen, creatinine, alkaline phosphatase, magnesium, phosphorus, TP1NP, OPG, BNP, LVMI, peak VO₂, and VE/VCO₂ slope were highest in the third tertile. In contrast, iron, ferritin, total protein, albumin, calcium, corrected calcium, sodium, and C-reactive protein did not differ among the groups. Echocardiographic parameters, except for LVMI, showed no statistical differences among the tertiles (Table 2). The available data of cardiopulmonary exercise testing (n = 250) are shown in Table 2. The peak VO₂ was lowest and VE/VCO₂ slope was highest in the third tertile.

Regarding factors that might affect serum TRACP5b levels, multiple regression analysis (Table 3) showed that age was an independent predictor of serum TRACP5b levels (β = 0.123; P = 0.003). Additionally, correlation analyses with the serum TRACP5b levels and other parameters are presented in Table 4. There were significant correlations between serum TRACP5b levels and hemoglobin, eGFR, alkaline phosphatase, phosphorus, TP1NP, OPG, BNP, LVMI, peak VO₂, and VE/VCO₂ slope.

In the follow-up period (range 4-1109, mean 426 days), there were 39 cardiac deaths and 113 cardiac events (39 cardiac deaths and 74 unplanned rehospitalizations because of worsening HF). In the Kaplan-Meier analysis (Fig. 1), cardiac mortality and cardiac event rates progressively increased from the first to the third tertiles (cardiac mortality, 3.1%, 5.2%, and 8.7%, log rank P = 0.024; cardiac event rates, 11.8%, 15.3%, and 22.2%, log rank P = 0.010). In the Cox proportional hazard analysis (Table 5), after adjusting for other confounding factors, high TRACP5b level was an independent predictor of cardiac mortality (hazard ratio, 2.493; 95% confidence interval, 1.041-5.974; P = 0.040) and cardiac event rates (hazard ratio, 1.687; 95% confidence interval, 1.051-2.707; P = 0.030) in HF patients. Even in cases of quartile or quintile models, high TRACP5b levels were associated with high incidence of cardiac mortality and cardiac event rates (log rank P < 0.05, respectively).

Additionally, OPG levels were partly measured in 255 of the 688 patients (Table 2). High OPG levels in HF patients were associated with high incidence of cardiac mortality and cardiac event rates (log rank P < 0.05, respectively).

Discussion

To our knowledge, the present study is the first to report that high TRACP5b levels in patients with HF are associated with high cardiac mortality and cardiac events, accompanied by high OPG levels, left ventricular hypertrophy, and impaired exercise capacity.
Table 2. Comparisons of parameters of laboratory data, echocardiography and cardiopulmonary exercise tests (N = 688)

| Characteristic                          | TRACP5b < 316 (n = 229) | TRACP5b 316-489 (n = 229) | TRACP5b ≥ 490 (n = 230) | P       |
|----------------------------------------|-------------------------|---------------------------|-------------------------|---------|
| Laboratory data                         |                         |                           |                         |         |
| WBC, × 10^3/μL                          | 7.7 ± 4.2               | 7.2 ± 3.1                 | 6.4 ± 2.2*              | < 0.001 |
| Hemoglobin, g/dL                       | 13.3 ± 2.1              | 13.0 ± 2.0                | 12.7 ± 2.3*             | 0.003   |
| Iron, μg/dL                             | 82.3 ± 40.9             | 81.2 ± 42.7               | 79.5 ± 42.7             | 0.830   |
| Ferritin, ng/mL                        | 179.7 ± 354.8           | 287.9 ± 1699.4            | 376.8 ± 3112.1          | 0.696   |
| Uric acid, μg/dL                       | 239.1 ± 75.7            | 243.4 ± 72.8              | 244.0 ± 78.5            | 0.534   |
| BUN, mg/dL                              | 19.7 ± 9.2              | 19.0 ± 9.1                | 23.0 ± 13.7*            | < 0.001 |
| Creatinine, mg/dL                      | 1.0 ± 0.5               | 1.0 ± 0.4                 | 1.1 ± 0.9               | 0.009   |
| eGFR, mL/min/1.73 cm^2                 | 60.3 ± 22.3             | 59.8 ± 18.9               | 54.7 ± 23.5*            | 0.013   |
| Total protein, g/dL                    | 7.0 ± 0.8               | 7.0 ± 0.7                 | 7.0 ± 0.8               | 0.897   |
| Albumin, g/dL                          | 3.9 ± 0.6               | 3.8 ± 0.6                 | 3.8 ± 0.6               | 0.217   |
| ALP, IU/L                              | 237.0 ± 133.3           | 258.3 ± 87.4              | 300.2 ± 150.6           | < 0.001 |
| Magnesium, mg/dL                       | 1.7 ± 0.2               | 1.7 ± 0.2                 | 1.8 ± 0.2*              | < 0.001 |
| Calcium, mg/dL                         | 9.0 ± 0.7               | 9.0 ± 0.6                 | 9.1 ± 0.6               | 0.113   |
| Corrected calcium, mg/dL               | 9.3 ± 0.5               | 9.4 ± 0.6                 | 9.4 ± 1.0               | 0.453   |
| Phosphorus, mEq/L                      | 3.5 ± 0.7               | 3.6 ± 0.7                 | 3.7 ± 0.6               | 0.049   |
| TP1NP, μg/L                            | 35.2 ± 20.4             | 50.7 ± 52.9*              | 77.5 ± 68.8*            | < 0.001 |
| OPG, pg/mL                             | 207.1 ± 136.9           | 219.0 ± 157.6             | 265.3 ± 178.2           | 0.051   |
| Sodium, mmol/L                         | 139.4 ± 3.6             | 140.0 ± 3.0               | 139.2 ± 4.4             | 0.117   |
| Potassium, mmol/L                      | 4.3 ± 0.5               | 4.2 ± 0.5                 | 4.2 ± 0.5               | 0.202   |
| Chloride, mmol/L                       | 104.1 ± 4.0             | 104.2 ± 3.6               | 103.1 ± 4.7             | 0.014   |
| CRP, mg/dL                             | 0.2 (0-1.0)             | 0.2 (0.1-0.8)             | 0.1 (0.1-0.6)           | 0.495   |
| BNP, pg/ml                             | 163.8 (72.9-485.1)      | 256.8 (93.3-562.1)        | 338.9 (126.6-652.8)     | 0.003   |
| Echocardiography                        |                         |                           |                         |         |
| LVESV, mL                              | 119.2 ± 60.0            | 117.4 ± 64.2              | 118.4 ± 67.1            | 0.969   |
| LVESV, mL                              | 62.7 ± 49.0             | 63.9 ± 54.0               | 68.0 ± 55.0             | 0.658   |
| LVF, %                                 | 53.0 ± 16.6             | 51.4 ± 16.7               | 48.6 ± 16.8             | 0.081   |
| IVS, mm                                | 10.5 ± 2.4              | 10.4 ± 2.5                | 10.6 ± 2.7              | 0.775   |
| PW, mm                                 | 10.5 ± 2.4              | 10.4 ± 2.0                | 10.7 ± 2.3              | 0.500   |
| LVMI, g/m^2                             | 121.2 ± 41.7            | 123.8 ± 43.0              | 132.0 ± 46.3            | 0.044   |
| Left atrial volume mL                  | 72.4 ± 43.0             | 69.9 ± 45.2               | 73.9 ± 39.7             | 0.730   |
| TR-PG, mm Hg                           | 27.7 ± 16.3             | 29.2 ± 17.4               | 29.9 ± 17.4             | 0.534   |
| IVC, mm                                | 15.5 ± 4.5              | 15.6 ± 4.6                | 15.2 ± 5.3              | 0.651   |
| RV FAC, %                              | 41.5 ± 17.2             | 38.0 ± 12.8               | 38.8 ± 13.3             | 0.278   |
| Cardiopulmonary exercise test, n = 250 |                         |                           |                         |         |
| Peak VO2, mL/kg/min                    | 15.6 ± 4.5              | 15.5 ± 5.0                | 13.9 ± 4.5              | 0.033   |
| VE/VO2 slope                           | 33.1 ± 7.7              | 34.8 ± 9.3                | 36.7 ± 9.0             | 0.034   |

Data are presented as mean ± SD or median (interquartile range) except where otherwise noted.
ALP, alkaline phosphatase; BNP, B-type natriuretic peptide; BUN, blood urea nitrogen; CRP, C-reactive protein; eGFR; estimated glomerular filtration rate; IVC, inferior vena cava; IVS, interventricular septum; LVESD, left ventricular end-diastolic volume; LVF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; LVMI, left ventricular mass index; OPG, osteoprotegerin; PW, posterior wall; RV FAC, right ventricular fractional area change; TP1NP, total procollagen type I intact N-terminal propeptide; TRACP5b, tartrate-resistant acid phosphatase type 5b; TR-PG, tricuspid regurgitation pressure gradient; UIC, unsaturated iron binding capacity; VE/VO2 slope, slope of the relationship between ventilation and carbon dioxide production; VO2, breath-by-breath oxygen consumption; WBC, white blood cell count.

* P < 0.01 vs first tertile.
+ P < 0.05.
1 P < 0.01 vs second tertile.
2 P < 0.05.

Table 3. Multiple regression analysis to determine serum TRACP5b levels

| Factor                        | Univariable     | P       | Multivariable | P       |
|-------------------------------|-----------------|---------|--------------|---------|
| Age                           | 0.207           | < 0.001 | 0.168        | < 0.001 |
| Female sex                    | 0.010           | 0.005   |              | 0.073   | 0.055 |
| NYHA functional class III/ IV | -0.023          | 0.546   |              | 0.007   | 0.007 |
| Ischemic etiology             | -0.016          | 0.666   |              |         |      |
| Hypertension                  | -0.005          | 0.887   |              |         |      |
| Diabetes                      | 0.025           | 0.658   |              | 0.032   | 0.426 |
| Dyslipidemia                  | -0.031          | 0.421   |              | 0.006   | 0.086 |
| Chronic kidney disease        | 0.104           | 0.006   |              | 0.066   | 0.426 |
| Anemia                        | 0.117           | 0.002   |              | 0.006   | 0.086 |
| Atrial fibrillation           | 0.055           | 0.148   |              |         |      |

NYHA, New York Heart Association; TRACP5b, tartrate-resistant acid phosphatase type 5b.
resorption markers; bone alkaline phosphatase, intact osteocalcin and TP1NP as bone formation markers; and receptor activator of nuclear factor κB ligand (RANKL) as a regulator of bone turnover. In addition, RANKL and OPG as regulators of bone turnover are very important factors in bone remodelling. These are members of the tumour necrosis factor superfamily that are critical regulators in bone metabolism, and appear also to be involved in immune response. In addition, impaired renal function is associated with anemia, increased parathyroid hormone concentrations, and osteoporosis. Thus, TRACP5b levels seemed to be correlated with TP1NP, OPG, alkaline phosphatase, hemoglobin, and eGFR in the present study.

Regarding associations of cardiovascular disease with biochemical markers for osteoporosis, OPG and RANKL have been reported. OPG activates tumour necrosis factor α and progresses vascular atherosclerosis and calcification. The plasma concentration of OPG increases with age in a healthy population, and is elevated in patients with cardiac hypertrophy, myocardial infarction, and HF. LVMI is gradually increased with reduced BMD. Concordant with previous reports, TRACP5b levels were correlated with LVMI in the present study. In addition, OPG is independently related to the incidence of HF hospitalization in patients with ischemic HF. Furthermore, higher OPG levels predict poor prognosis such as higher all-cause mortality and hospitalization for worsening of HF in patients with HF. Regarding exercise capacity, it has been reported that exercise capacity determined using cardiopulmonary exercising testing (ie, peak VO₂ and exercise duration) was impaired in patients who had osteoporosis for >5 years than in those who had osteoporosis for <5 years. In addition, osteoporosis is associated with kyphosis-related respiratory dysfunction, muscle weakness, and leads to impaired exercise capacity. Concordant with these data, in the present study, high TRACP5b levels were associated with LVMI and impaired exercise capacity (lower peak VO₂ and higher VE/VCO₂ slope).

RANKL is a chemotactic factor that stimulates chemokine release and matrix metalloproteinase activity, promotes inflammatory response in T cells, is required for normal development of lymph nodes, and causes left ventricular remodelling. OPG and RANKL have recently been considered as new signalling molecules, mediators, and potential biomarkers for atherosclerosis, and it is reported that the serum levels of OPG and RANKL are higher in HF patients. However, it is difficult to measure OPG and RANKL in daily clinical settings. On the contrary, measuring TRACP5b is used in daily clinical settings for screening for osteoporosis or evaluating therapeutic effects on osteoporosis. Serum TRACP5b activity has a low diurnal variability, its

Table 4. Correlation analysis with TRACP5b and other parameters

| Parameter                                      | R   | P     |
|------------------------------------------------|-----|-------|
| Laboratory data                                |     |       |
| Hemoglobin                                     | −0.150 | < 0.001 |
| eGFR                                           | −0.129 | 0.001 |
| Total protein                                  | 0.007 | 0.854 |
| Albumin                                        | −0.075 | 0.071 |
| Alkaline phosphatase                           | 0.247 | < 0.001 |
| Magnesium                                      | 0.072 | 0.122 |
| Calcium                                        | 0.062 | 0.108 |
| Corrected calcium                              | 0.037 | 0.367 |
| Phosphorus                                     | 0.100 | 0.009 |
| TP1NP                                          | 0.400 | < 0.001 |
| OPG                                            | 0.204 | 0.001 |
| Sodium                                         | −0.041 | 0.291 |
| Potassium                                      | −0.021 | 0.584 |
| Chloride                                       | −0.113 | 0.004 |
| Log CRP                                        | −0.060 | 0.071 |
| Log BNP                                        | 0.188 | < 0.001 |
| Echocardiography                               |     |       |
| LVMI                                           | 0.090 | 0.025 |
| Left atrial volume                             | 0.017 | 0.733 |
| TR-PG                                          | 0.025 | 0.564 |
| IVC                                            | −0.047 | 0.246 |
| RV FAC                                         | 0.015 | 0.816 |
| Cardiopulmonary exercise test                  |     |       |
| Peak VO₂                                       | −0.159 | 0.012 |
| VE/VCO₂ slope                                  | 0.180 | 0.004 |

BNP, B-type natriuretic peptide; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; IVC, inferior vena cava; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; OPG, osteoprotegerin; RV FAC, right ventricular fractional area change; TP1NP, total procollagen type I intact N-terminal propeptide; TRACP5b, tartrate-resistant acid phosphatase type 5b; TR-PG, tricuspid regurgitation pressure gradient; VE/VCO₂ slope, slope of the relationship between ventilation and carbon dioxide production; VO₂, breath-by-breath oxygen consumption.

Figure 1. Accumulated event rates of cardiac deaths and cardiac events stratified according to serum tartrate-resistant acid phosphatase type 5b (TRACP5b) levels.
level is not affected by feeding, and it does not accumulate in the circulation in cases of renal or hepatic failure, which are often complicated with HF; thus, in the serum samples TRACP5b might be easier to measure than other osteoporotic biomarkers especially in HF patients. Although there have been no reports on the relationships among OPG, RANKL, and TRACP5b in HF patients, it has been reported that serum TRACP5b levels are positively correlated with plasma OPG levels in patients with coronary artery disease. Concordant with the results, we first presented that TRACP5b levels were positively correlated with plasma OPG levels in HF patients. In addition, the serum levels of C-terminal cross-linked telopeptides of type I collagen, which is a marker of bone resorption as well as TRACP5b, are positively correlated with the bone marrow plasma levels of RANKL in HF patients. In these regards, the serum TRACP5b levels might reflect OPG and RANKL, indicating bone remodelling, and could affect adverse prognosis in HF patients.

### Table 5. Cox proportional hazard model of cardiac mortality and cardiac events in patients with heart failure

| Risk factor                                              | Univariable | Multivariable |
|----------------------------------------------------------|-------------|---------------|
|                                                         | HR  | 95% CI   | P       | HR  | 95% CI   | P       |
| Cardiac mortality (39 events/N = 688)                   |     |          |         |     |          |         |
| Age ≥ 75 years, yes = 1                                 | 1.033| 1.007-1.059 | 0.013  | 1.545| 0.795-3.002 | 0.200  |
| Female sex, yes = 1                                     | 0.667| 0.342-1.297 | 0.233  |      |          |         |
| NYHA functional class III/IV                            | 2.366| 1.241-4.512 | 0.009  | 1.956| 1.011-3.785 | 0.046  |
| Systolic blood pressure, mm Hg                          | 0.995| 0.982-1.008 | 0.429  |      |          |         |
| Ischemic etiology, yes = 1                              | 1.499| 0.759-2.962 | 0.244  |      |          |         |
| Reduced EF ≤ 40%, yes = 1                               | 2.217| 1.176-4.178 | 0.013  | 1.727| 0.893-3.340 | 0.105  |
| Hypertension, yes = 1                                   | 0.979| 0.514-1.867 | 0.494  |      |          |         |
| Diabetes, yes = 1                                       | 2.639| 1.384-5.033 | 0.003  | 2.115| 1.093-4.093 | 0.026  |
| Chronic kidney disease, yes = 1                         | 2.959| 1.403-6.241 | 0.004  | 2.140| 0.987-4.640 | 0.054  |
| Anemia, yes = 1                                         | 1.309| 0.697-2.457 | 0.405  |      |          |         |
| Arrial fibrillation, yes = 1                            | 1.567| 0.835-2.942 | 0.162  |      |          |         |
| TRACP5b First tertile Reference                         |     |          |         |      |          |         |
| Second tertile                                          | 1.651| 0.650-4.193 | 0.292  |      |          |         |
| Third tertile                                           | 2.977| 1.258-7.044 | 0.013  | 2.493| 1.041-5.974 | 0.040  |
| Cardiac events (113 events/n = 688)                     |     |          |         |      |          |         |
| Age ≥ 75, yes = 1                                       | 1.032| 1.016-1.048 | < 0.001 | 1.835| 1.237-2.724 | 0.003  |
| Female sex, yes = 1                                     | 0.980| 0.664-1.447 | 0.920  |      |          |         |
| NYHA functional class III/IV                            | 1.657| 1.128-2.435 | 0.010  | 1.302| 0.891-1.902 | 0.173  |
| Systolic blood pressure, mm Hg                          | 0.995| 0.988-1.003 | 0.246  |      |          |         |
| Ischemic etiology, yes = 1                              | 0.936| 0.589-1.489 | 0.781  |      |          |         |
| Reduced EF ≤ 40%, yes = 1                               | 1.115| 0.765-1.626 | 0.570  |      |          |         |
| Hypertension, yes = 1                                   | 1.401| 0.924-2.125 | 0.112  |      |          |         |
| Diabetes, yes = 1                                       | 1.609| 1.095-2.365 | 0.015  | 1.663| 1.144-2.418 | 0.008  |
| Anemia, yes = 1                                         | 1.576| 1.035-2.351 | 0.026  | 1.184| 0.785-1.788 | 0.420  |
| Arrial fibrillation, yes = 1                            | 2.353| 1.565-3.536 | < 0.001 | 1.441| 0.963-2.157 | 0.076  |
| TRACP5b First tertile Reference                         |     |          |         |      |          |         |
| Second tertile                                          | 1.243| 0.736-2.097 | 0.416  | 1.128| 0.681-1.870 | 0.639  |
| Third tertile                                           | 1.997| 1.229-3.245 | 0.005  | 1.687| 1.051-2.707 | 0.030  |

CI, confidence interval; EF, ejection fraction; HR, hazard ratio; NYHA, New York Heart Association; TRACP5b, tartrate-resistant acid phosphatase type 5b.

Figure 2. Accumulated event rates of cardiac deaths and cardiac events stratified according to serum osteoprotegerin (OPG) levels.
Study strengths and limitations

Our study has several strengths. For example, this is the first study, to our knowledge, to show the association of increased serum TRACP5b with adverse prognosis in HF patients, taking into consideration multifaceted clinical backgrounds such as laboratory tests, echocardiography, and exercise capacity. Second, we were able to follow-up on all patients and we enrolled more study subjects than previous studies.33,38

The present study has several limitations. First, because it was a single-centre study with a relatively small number of study subjects, the present results might not necessarily be representative of a general HF population. Although we performed multivariate Cox proportional hazard analysis, we cannot rule out residual confounding factors. Second, although blood samples were obtained when the patients were in stable condition before hospital discharge in the present study, sampling at hospital admission without any therapy might be preferable to examine the prognostic effect of TRACP5b. Third, in the present study we included several variables during hospitalization, without taking into consideration changes in any parameters and treatments during the post-discharge follow-up period. Fourth, we could not necessarily perform cardiopulmonary exercise testing in all of the patients because of various reasons (eg, medical reasons, patient refusal, etc), and potential selection bias might exist in these measurements. Fifth, we could not examine the dual-energy x-ray absorptiometry in all patients, which is standard for osteoporosis, because of implantable devices. Sixth, we did not examine markers of osteoporosis, other than TRACP5b, TP1NP, and OPG in the present study. Seventh, because this was a cross-sectional and prospective observational study without any intervention for osteoporosis, the causal relationships between increased TRACP5b and worse prognosis could not be fully explained. Therefore, the present results should be viewed as preliminary, and further studies are needed.

Conclusions

Increased serum levels of TRACP5b, a marker of bone resorption, is associated with adverse prognosis, accompanied by impaired exercise capacity, in HF patients.

Acknowledgements

The authors thank Ms Kumiko Watanabe, Ms Yumi Yoshihisa, and Ms Tomiko Miura for their technical assistance.

Funding Sources

This work was supported in part by a grant-in-aid for Scientific Research (20K07828 and 20K17157) from the Japan Society for the Promotion of Science, Tokyo, Japan.

Disclosures

The authors have no conflicts of interest to disclose.

References

1. Tsutsui H, Isobe M, Ito H, et al. JCS 2017/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure—digest version. Circ J 2019;83:2084-184.

2. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129-200.

3. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147-239.

4. Pfister R, Michels G, Sharp SJ, et al. Low bone mineral density predicts incident heart failure in men and women: the EPIC (European Prospective Investigation into Cancer and Nutrition)-Norfolk prospective study. JACC Heart Fail 2014;2:380-9.

5. Kuo TR, Chen CH. Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives. Biomark Res 2017:5:18.

6. Lv Y, Wang G, Xu W, et al. Tartrate-resistant acid phosphatase 5b is a marker of osteoclast number and volume in RAW 264.7 cells treated with receptor-activated nuclear kappaB ligand. Exp Ther Med 2015;9:143-6.

7. Morisawa T, Nakagomi A, Kohashi K, Kusama Y, Shimizu W. Serum tartrate-resistant acid phosphatase-5b levels are associated with the severity and extent of coronary atherosclerosis in patients with coronary artery disease. J Atheroscler Thromb 2017;24:1058-68.

8. Hao Y, Tsuruda T, Sekita-Hatakeyama Y, et al. Cardiac hypertrophy is exacerbated in aged mice lacking the osteoprotegerin gene. Cardiovasc Res 2016;110:62-72.

9. Aluoch AO, Jesse R, Habal H, et al. Heart failure as a risk factor for osteoporosis and fractures. Curr Osteoporos Rep 2012;10:258-69.

10. Terrovitis J, Zotos P, kaldara E, et al. Bone mass loss in chronic heart failure is associated with secondary hyperparathyroidism and has prognostic significance. Eur J Heart Fail 2012;14:326-32.

11. Chen YH, Wu YW, Yang WS, et al. Relationship between bone mineral density and serum osteoprotegerin in patients with chronic heart failure. PLoS One 2012;7:e44242.

12. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891-975.

13. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013;128:1810-52.

14. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971;285:1441-6.

15. Rickham PP. Human experimentation. Code of ethics of the World Medical Association. Declaration of Helsinki. Br Med J 1964;2:177.

16. von Elm E, Altman DG, Egger M, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007;335:806-8.

17. Yoshihisa A, Ichijo Y, Watanabe K, et al. Prior history and incidence of cancer impacts on cardiac prognosis in hospitalized patients with heart failure. Circ J 2019;83:1709-17.
18. Yoshihisa A, Sato Y, Kanno Y, et al. Prognostic impacts of changes in left ventricular ejection fraction in heart failure patients with preserved left ventricular ejection fraction. Open Heart 2020;7:e001112.

19. Yoshihisa A, Takiguchi M, Shimizu T, et al. Cardiovascular function and prognosis of patients with heart failure coexistent with chronic obstructive pulmonary disease. J Cardiol 2014;64:256-64.

20. Sato A, Yoshihisa A, Kanno Y, et al. Associations of dipeptidyl peptidase-4 inhibitors with mortality in hospitalized heart failure patients with diabetes mellitus. ESC Heart Fail 2016;3:77-85.

21. Yoshihisa A, Watanabe S, Kanno Y, et al. The CHA2 DS2-VASc score as a predictor of high mortality in hospitalized heart failure patients. ESC Heart Fail 2016;3:261-9.

22. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005;67:2089-100.

23. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982-92.

24. Yoshihisa A, Sato Y, Sato T, et al. Better clinical outcome with direct oral anticoagulants in hospitalized heart failure patients with atrial fibrillation. BMC Cardiovasc Disord 2018;18:11.

25. Iki M, Fujita Y, Tamaki J, et al. Design and baseline characteristics of a prospective cohort study for determinants of osteoporotic fracture in community-dwelling elderly Japanese men: the Fujiwara-kyo osteoporosis risk in men (FORMEN) study. BMC Musculoskelet Disord 2009;10:165.

26. Blumsohn A, Marin F, Nickelsen T, et al. Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide. Osteoporos Int 2011;22:1935-46.

27. Garnero P, Vergnaud P, Hoyle N. Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin Chem 2008;54:188-96.

28. Sawicka-Powierza J, Jablonska E, Ratajczak-Wrona W, et al. Bone metabolism markers and bone mineral density in long-term acnecoumarol treatment: a cross-sectional study. J Clin Med 2018;7:372.

29. Kim BJ, Hamrick MW, Yoo HJ, et al. The detrimental effects of kynurenine, a tryptophan metabolite, on human bone metabolism. J Clin Endocrinol Metab 2019;104:2334-42.

30. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006;7:79-108.

31. Yoshihisa A, Ichijo Y, Sato Y, et al. Comprehensive clinical characteristics of hospitalized patients with mid-range left ventricular ejection fraction. Eur J Prev Cardiol 2020;27:2084-8.

32. Kanno Y, Yoshihisa A, Watanabe S, et al. Prognostic significance of insomnia in heart failure. Circ J 2016;80:1571-7.

33. Ueland T, Yndestad A, Oie E, et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 2005;111:2461-8.

34. Chen H, Lips P, Vervloet MG, van Schoor NM, de Jongh RT. Association of renal function with bone mineral density and fracture risk in the Longitudinal Aging Study Amsterdam. Osteoporos Int 2018;29:2129-38.

35. Huang C, Li S. Correlation research between osteoporosis and left ventricular hypertrophy in older men. Arch Med Sci 2016;12:1220-4.

36. Ueland T, Dahl CP, Kjekshus J, et al. Osteoprotegerin predicts progression of chronic heart failure: results from CORONA. Circ Heart Fail 2011;4:145-52.

37. Ordu Gokkaya NK, Koseoglu F, Albayrak N. Reduced aerobic capacity in patients with severe osteoporosis: a cross sectional study. J Phys Rehabil Med 2008;44:141-7.

38. Raaz-Schrauder D, Schrauder MG, Stumpf C, et al. Plasma levels of sRANKL and OPG are associated with atherogenic cytokines in patients with intermediate cardiovascular risk. Heart Vessels 2017;32:1304-13.

39. Shiraki M, Kuroda T, Shiraki Y, et al. Urinary pentosidine and plasma homocysteine levels at baseline predict future fractures in osteoporosis patients under bisphosphonate treatment. J Bone Miner Metab 2011;29:62-70.

40. Leistner DM, Seeger FH, Fischer A, et al. Elevated levels of the mediator of catabolic bone remodeling RANKL in the bone marrow environment link chronic heart failure with osteoporosis. Circ Heart Fail 2012;5:769-77.